With its high tumor uptake, fast clearance from nontarget organs, and nontoxic profile, the novel PSMA-targeting hybrid molecule qualifies for a clinical translation and strongly encourages realization and extended preclinical investigation of related PSMA-inhibitor designs. The gene discussed is FOLH1; the disease is neoplasm.